AstraZeneca: raises annual sales and EPS forecasts
(CercleFinance.com) - AstraZeneca reports Q2 sales of $12.
9bn, up 13% (+17% at constant exchange rates).
Activity is mainly divided between oncology (22%), cardiovascular, renal and metabolic diseases (22%), respiratory and immunology (22%) and rare diseases (15%).
Quarterly net income reached $1,928m (vs. $1,820m a year earlier).
Core EPS comes in at $1.98, down 8% (or -3% at constant exchange rates).
The company has revised upwards its full-year sales and EPS forecasts, and is now targeting total sales growth of around 15% (vs. a low double-digit percentage previously). Basic EPS is also expected to rise by% (vs. a low double-digit percentage previously).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
9bn, up 13% (+17% at constant exchange rates).
Activity is mainly divided between oncology (22%), cardiovascular, renal and metabolic diseases (22%), respiratory and immunology (22%) and rare diseases (15%).
Quarterly net income reached $1,928m (vs. $1,820m a year earlier).
Core EPS comes in at $1.98, down 8% (or -3% at constant exchange rates).
The company has revised upwards its full-year sales and EPS forecasts, and is now targeting total sales growth of around 15% (vs. a low double-digit percentage previously). Basic EPS is also expected to rise by% (vs. a low double-digit percentage previously).
Copyright (c) 2024 CercleFinance.com. All rights reserved.